Beckley Psytech

Beckley Psytech was a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the Beckley Foundation — the UK-based psychedelic research charity co-founded by Amanda Feilding. The company focused on developing novel proprietary psychedelic formulations, with its lead asset BPL-003, an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) for treatment-resistant depression. BPL-003 received FDA Breakthrough Therapy Designation and delivered positive Phase 2b results. In November 2025, Beckley Psytech merged with atai Life Sciences in an all-share transaction to form AtaiBeckley, with BPL-003 becoming the lead asset of the combined company.